Table 1.

Clinicopathological features and immune features of the primary tumor.

	All cases	HER2	TNBC		sTILs < 20%	sTILs≥20%
	n = 161 (%)	n = 62 (%)	n = 99 (%)	P value	n = 86 (%)	n = 75 (%)	P value
sTILs
<20%	86 (53)	34 (55)	52 (52)		/	/	/
≥20%	75 (47)	28 (45)	47 (48)	0.775^a	/	/	/
Tertiary lymphoid structures
Absent	123 (76)	46 (74)	77 (78)		72 (84)	51 (68)
Present	38 (24)	16 (26)	22 (22)	0.602^a	14 (16)	24 (32)	0.019^a
Age at diagnosis
<50	66 (41)	20 (32)	46 (46)		35 (41)	31 (41)
≥50	95 (59)	42 (68)	53 (54)	0.074^a	51 (59)	44 (59)	0.935^a
Tumor size
pT1	33 (21)	11 (18)	22 (22)		12 (14)	21 (28)
pT2	116 (72)	46 (74)	70 (71)		65 (76)	51 (68)
pT3	10 (6)	4 (6)	6 (6)		8 (9)	2 (3)
pT4	2 (1)	1 (2)	1 (1)	0.906^a	1 (1)	1 (1)	0.071^a
Histological grade
III	161 (100)	62 (100)	99 (100)		86 (100)	75 (100)
Lymphovascular invasion
Absent	51 (32)	13 (21)	38 (38)		24 (28)	27 (36)
Present	110 (68)	49 (79)	61 (62)	0.021^a	62 (72)	48 (64)	0.271^a
Lymph node status
pN1 (1–3)	90 (56)	27 (44)	63 (64)		47 (55)	43 (57)
pN2 (4–9)	39 (24)	18 (29)	21 (21)		20 (23)	19 (25)
pN3 (>=10)	32 (20)	17 (27)	15 (15)	0.037^a	19 (22)	13 (18)	0.748^a
Chemotherapy
Anthracycline + taxane	137 (85)	55 (89)	82 (83)		77 (90)	60 (80)
Anthracycline	19 (12)	5 (8)	14 (14)		7 (8)	12 (16)
Taxane	5 (3)	2 (3)	3 (3)	0.508^a	2 (2)	3 (4)	0.236^a
Local or regional tumor recurrence
Absent	144 (89)	55 (89)	89 (90)		73 (85)	71 (95)
Present	17 (11)	7 (11)	10 (10)	0.811^a	13 (15)	4 (5)	0.044^a
Distant metastasis
Absent	119 (74)	46 (75)	73 (74)		52 (60)	67 (89)
Present	42 (26)	16 (25)	26 (26)	0.949^a	34 (40)	8 (11)	<0.001^a
Breast cancer-specific death
Absent	127 (79)	47 (76)	80 (81)		57 (66)	70 (93)
Present	34 (21)	15 (24)	19 (20)	0.449^a	29 (34)	5 (7)	<0.001^a

^aChi-squared test